ASCO 2021 Archives -

This has probably been the toughest year for oncology researchers in memory. As this issue’s contributors discuss, funding

Deep Dive: Oncology 2021

https://pharmaphorum.com/views-analysis-oncology/deep-dive-oncology-2021/

Novartis’ Kymriah has had the CAR-T therapy market for acute lymphoblastic leukaemia (ALL) to itself so far, but

ASCO21: Gilead sets up first FDA okay for CAR-T in adult ALL with Tecartus data

https://pharmaphorum.com/news/asco21-gilead-sets-up-first-fda-okay-for-adult-all-with-tecartus-data/

AstraZeneca and Merck & Co’s Lynparza is primed for even wider use in the treatment of breast cancer

ASCO21: Lynparza aces adjuvant breast cancer therapy trial

https://pharmaphorum.com/news/asco21-lynparza-aces-adjuvant-breast-cancer-therapy-trial/

Novartis’ big investment in radiopharmaceuticals for cancer seems to have paid off, after lead candidate 177Lu-PSMA-617 helped men

ASCO21: Novartis’ prostate cancer radiotherapy extends survival

https://pharmaphorum.com/news/asco21-novartis-prostate-cancer-radiotherapy-extends-survival/

ASCO 2021